Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA481: Immunosuppressive therapy for kidney transplant in adults for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | mycophenolic acid (Myfortic®) | |
| Formulation | tablet | |
| Reference number | 210 | |
| Indication | In combination with ciclosporin & corticosteroids, for the prophylaxis of acute transplant rejection in adult patients receiving allogneic renal transplants |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 02/03/2006 | |
| Ratification by Welsh Government | 07/06/2006 | |
| Date of issue | 13/06/2006 | |
| NICE guidance | TA481: Immunosuppressive therapy for kidney transplant in adults |
|